Regeneron Pharmaceuticals, Inc. (REGN) closed Tuesday at $920.37, a gain of 1.80% on the session. The move added to what has been a notable stretch of outperformance for the biotech giant over the past month.
Over the trailing 30 days, REGN has advanced 23.28%, a rally that has pushed the company's market capitalization to $93.55 billion. The stock's monthly performance stands as one of the more significant moves in the large-cap biotech space in recent weeks.
Despite Tuesday's gain, the stock remains under modest pressure on a weekly basis, down 4.27% over the past seven days. That pullback suggests the shares encountered selling pressure at some point during the week before recovering ground in Tuesday's session.
Regeneron's market cap of $93.55 billion reflects its standing as one of the larger biotechnology companies by valuation. As of November 10, 2026, the stock's price of $920.37 places it near the upper end of its recent trading range established during the 30-day advance.
